Insulin Resistance and Atherosclerosis in Women With Lupus
NCT00544102 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2019-12-17
Summary
This study will test the effects of insulin resistance on atherosclerosis (hardening of the arteries) in women who have systemic lupus erythematosus, more commonly known as lupus. Women with lupus have a higher chance of developing atherosclerosis than the general population, and as a result are more susceptible to heart attack and stroke. Insulin resistance is a particular risk factor for atherosclerosis, and recent small studies have shown that insulin resistance is more common in lupus patients than in those without lupus. The study will consist of a series of tests designed to assess whether there is an association between insulin resistance and atherosclerosis in women with lupus. This research may lead to further studies on possible treatments to reduce the risk of heart disease in lupus patients.
Volunteers must be women between 30 and 55 years of age who were diagnosed with lupus within five or more years prior to the study. Volunteers who have kidney failure, diabetes, or existing atherosclerosis will be excluded from the study, as will volunteers who have had pulse steroid therapy within four weeks of the testing or who have been pregnant within one year of the testing.
Participants will undergo the following procedures on an outpatient basis:
* Blood and urine tests for research purposes.
* Electrocardiogram (EKG) to test the general health of the heart.
* Oral glucose tolerance test to measure blood glucose and insulin levels. This test is commonly used to diagnose diabetes and pre-diabetic insulin resistance.
* Cardiac multidetector computed tomography (MDCT) to determine the amount of calcium present in coronary arteries. This test is used to diagnose atherosclerosis.
* Carotid artery ultrasound to show the speed of blood flow through the carotid arteries. This test will show abnormalities and/or blockages in the carotid arteries.
* Abdominal ultrasound to determine if the participant has hepatic steatosis ( fatty liver ), which is often found in individuals with insulin resistance and diabetes.
* Carotid artery magnetic resonance imaging/angiogram (MRI/MRA) to measure the thickness of blood vessels. This test is used to diagnose atherosclerosis.
* Abdominal MRI to estimate abdominal fat.
Volunteers may be asked to participate in an MRI/MRA study to evaluate the arteries of the heart. This test is optional and not required by the insulin resistance/atherosclerosis study. The entire series of procedures will require one to three visits to complete.
Conditions
Sponsors & Collaborators
-
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
lead NIH
Principal Investigators
-
Sarfaraz A Hasni, M.D. · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Eligibility
- Min Age
- 30 Years
- Max Age
- 55 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-10-11
- Completion
- 2017-09-07
Countries
- United States
Study Locations
More Related Trials
-
A Study of the Metabolic Syndrome in Patients With Systemic Lupus Erythematosus
NCT00982670 ·Status: COMPLETED
-
Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)
NCT02338999 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Relation of Antibodies Against Oxidized Low Density Lipoproteins to Disease Activity and Cardiovascular Affection in Systemic Lupus.
NCT05479071 ·Status: UNKNOWN
-
Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic Lupus Erythematosus or Sharp's Syndrome
NCT02741362 ·Status: TERMINATED ·Phase: PHASE1
-
Safety Study of AMG 557 in Subjects With Lupus Arthritis
NCT01683695 ·Status: COMPLETED ·Phase: PHASE1
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
NCT05440422 ·Status: RECRUITING ·Phase: PHASE2
-
Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)
NCT00054938 ·Status: COMPLETED ·Phase: PHASE2
-
Immune Mediators and Metabolites to Stratify Systemic Lupus Erythematosus Patients at High Risk of Cardio Vascular Diseases
NCT04276701 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Women Empowered to Live With Lupus Study
NCT02988661 ·Status: COMPLETED ·Phase: NA
-
Steroid-induced Diabetes Mellitus in Systemic Lupus Erythematosus (SLE) Patients
NCT04024306 ·Status: UNKNOWN
-
Disease Progression and Activity in Patients With Systemic Lupus Erythematosus
NCT00339261 ·Status: COMPLETED
-
Observational Study Investigating Demographic and Clinical Characteristics of SLE Patients in Egypt
NCT07144514 ·Status: NOT_YET_RECRUITING
-
Study of the Predictors of the Course and Early Outcome of Patients With Systemic Lupus Erythematosus: Nature Versus Nurture
NCT00006134 ·Status: COMPLETED
-
Gynecological Symptoms and Health-related Quality of Life in Egyptian Women With SLE
NCT05230316 ·Status: UNKNOWN
-
Cardiac and Laboratory Findings in Patients With Systemic Lupus Erythematosus
NCT03179046 ·Status: COMPLETED
-
Identifying New Therapeutic Targets for Lupus Treatment
NCT03921398 ·Status: COMPLETED
-
Cardiology Prevention in Systemic Lupus Erythematosus (SLE)
NCT00610805 ·Status: WITHDRAWN ·Phase: NA
-
Systemic Lupus Erythematous and Heart Conduction Disorders
NCT02162992 ·Status: COMPLETED
-
Premature Atherosclerosis in Systemic Lupus Erythematosus
NCT04037293 ·Status: UNKNOWN
-
Atherosclerosis in Rheumatoid Arthritis and Lupus: Restoring Cholesterol Balance
NCT01180361 ·Status: COMPLETED
-
Lupus Interval Monitoring to Manage Disease Flare and Enable Treatment Optimization
NCT03142412 ·Status: UNKNOWN
-
WEUKBRE5716: Steroid-related Damage in Systemic Lupus Erythematosus (Hopkins)
NCT01616472 ·Status: COMPLETED
-
Prognostic Factors for Fatigue in Patients With Systemic Lupus Erythematosus
NCT07123220 ·Status: COMPLETED
-
New Signaling Pathway Targeting Systemic Lupus Erythematosus
NCT03984227 ·Status: UNKNOWN
-
Epidemiologic Study of Reproductive Outcome in Women With Systemic Lupus Erythematosus
NCT00004663 ·Status: COMPLETED